Fonterra Research and Development Centre, Dairy Farm Road, Palmerston North 4442, New Zealand.
Nutrients. 2024 Sep 2;16(17):2936. doi: 10.3390/nu16172936.
BACKGROUND/OBJECTIVES: HN001 (HN001) is a probiotic strain widely studied for its potential to improve human health. Previous studies have demonstrated promising results for HN001 in the improvement of mental well-being, particularly in terms of increased happiness and support for stress management in healthy adults.
To further explore these findings, a double-blind, placebo-controlled trial was conducted with 120 participants aged ≥ 18 years with mild to high stress measured by the Perceived Stress Scale (PSS). The participants were randomly assigned to receive either HN001 or placebo for 28 days. Psychological assessments, including the Oxford Happiness Questionnaire (OHQ), were completed at baseline, day 14, and day 28. Secondary outcomes included changes in PSS scores, as well as depression, anxiety, stress, and total score levels measured by the DASS-21 questionnaire.
While not statistically significant, participants who received HN001 showed an improvement in OHQ (mean change, 13.3) and PSS total scores (mean change, -8.1) over time compared with the placebo group (mean change, 10.2 and -6.6, respectively). Furthermore, 39% of the participants moved from not happy to happy, compared with only 29% in the placebo group. Post-hoc analysis showed a statistically significant interaction between intervention and study day for OHQ and PSS total scores, with -values of 0.014 and 0.043, respectively. No adverse effects were observed.
HN001 showed improvements in both happiness and PSS scores. Furthermore, sex subgroup analysis revealed statistically significant differences in both outcomes, emphasizing the need for larger and longer intervention studies.
背景/目的:HN001(HN001)是一种被广泛研究的益生菌菌株,因其改善人类健康的潜力而备受关注。先前的研究表明,HN001 对改善心理健康具有广阔的前景,特别是在提高幸福感和支持压力管理方面对健康成年人有积极作用。
为了进一步探索这些发现,我们进行了一项双盲、安慰剂对照试验,共有 120 名年龄在 18 岁及以上、压力程度为轻度至高度的成年人参与,其压力程度通过感知压力量表(PSS)进行评估。参与者被随机分为 HN001 组或安慰剂组,分别接受 28 天的治疗。在基线、第 14 天和第 28 天进行心理评估,包括牛津幸福感问卷(OHQ)。次要终点包括 PSS 评分变化,以及 DASS-21 问卷评估的抑郁、焦虑、压力和总分水平的变化。
尽管无统计学意义,但与安慰剂组相比,接受 HN001 治疗的参与者在 OHQ(平均变化 13.3)和 PSS 总分(平均变化-8.1)方面随时间推移显示出改善,而安慰剂组分别为 10.2 和-6.6。此外,与安慰剂组相比,39%的参与者从不快乐变为快乐,而安慰剂组仅为 29%。事后分析显示,干预和研究日之间在 OHQ 和 PSS 总分上存在统计学显著的交互作用,相应的 P 值分别为 0.014 和 0.043。未观察到不良反应。
HN001 改善了幸福感和 PSS 评分。此外,性别亚组分析显示,这两个结果均存在统计学显著差异,强调需要更大规模和更长时间的干预研究。